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BACKgROUND: Infantile hemangioma is the most common benign,
self-limiting tumour of childhood. Treatment is reserved for hemangiomas that obstruct vital structures or cause significant disfigurement.
Traditionally, corticosteroids have been the medical treatment of choice.
Since 2008, however, propranolol has been rapidly adopted as an effective pharmacological treatment for infantile hemangioma. Published data
regarding the long-term side effects of propranolol are currently lacking.
OBJECTIVE: To describe the long-term effects of propranolol and corticosteroids on anthropometric measurements (height, body mass index
[BMI]) and blood pressure in children.
METHODS: A prospective database analysis of all infantile hemangioma patient visits to the pediatric vascular abnormality clinic at the
authors’ institution between October 2007 and February 2012 was performed. Anthropometric measures (height and BMI) and blood pressure
were analyzed.
RESULTS: A total of 290 visits (119 patients) to the pediatric vascular
abnormality clinic were reviewed. Of these, 18 patients received medical
treatment and their anthropometry was analyzed. BMI percentile increased
significantly in patients treated with corticosteroids (P=0.0039).
Corticosteroid treatment also resulted in a significant decrease in height
percentile (P=0.0078). Anthropometric measures did not cross percentiles
in children treated with propranolol. A significant decrease in systolic
blood pressure was noted in the propranolol group (P=0.03), but no hypotensive values were recorded. Median treatment duration was significantly
longer when patients received propranolol (372 versus 133 days; P=0.0033).
CONCLUSION: Propranolol for the treatment of infantile vascular
abnormalities does not share the unfavourable effects on patient anthropometry that corticosteroids exhibit; however, a longer duration of therapy
is required.
Key Words: Hemangioma; Multidisciplinary clinic, Prednisolone; Prednisone;
Propranolol; Surgical treatment

T

he vast majority of vascular anomalies of infancy and childhood
can be classified as hemangioma or vascular malformation (1).
Infantile hemangiomas (IHs), characterized by proliferating endothelial cells, are the most common benign vascular malformations
observed in children. They often present a few weeks after birth with
a rapid proliferating phase, followed by a period of quiescence and,
finally, involution (2). Given this characteristic natural history, the
majority of hemangiomas do not require treatment. Pharmacological
therapy with corticosteroids or interferon-alpha-2a is indicated for
lesions that threaten vital function or are grossly deforming (1). More
recently, two new developments have had a significant impact on the
management of IHs, namely the development of multidisciplinary
clinics and the introduction of the beta-blocker propranolol as a therapeutic option (2). A multidisciplinary clinic provides many advantages, including effective communication among care providers, more

Le traitement au propranolol est moins toxique,
mais plus long que la corticothérapie pour traiter
l’hémangiome infantile
HISTORIQUE : L’hémangiome infantile est la principale tumeur
bénigne autolimitative de l’enfance. Le traitement est réservé aux
hémangiomes qui obstruent des structures vitales ou provoquent une
importante défiguration. La corticothérapie était privilégiée, mais à
compter de 2008, le propranolol a rapidement été adopté en raison de
son efficacité. Il n’y a pas de données publiées sur les effets à long terme
du propranolol.
OBJECTIF : Décrire les effets à long terme du propranolol et des corticoïdes sur les mesures anthropométriques (taille, indice de masse corporelle [IMC]) et la tension artérielle chez les enfants.
MÉTHODOLOgIE : Les chercheurs ont effectué une analyse prospective des bases de données de toutes les visites de patients à la clinique
pédiatrique d’anomalies vasculaires de l’établissement des auteurs en
raison d’un hémangiome infantile entre octobre 2007 et février 2012.
Ils ont analysé les mesures anthropométriques (taille et IMC) et la tension artérielle.
RÉSULTATS : Les chercheurs ont examiné 290 visites (119 patients) à la
clinique pédiatrique d’anomalies vasculaires. De ce nombre, 18 patients
ont reçu un traitement médical. Les chercheurs ont évalué leurs mesures
anthropométriques. Le percentile d’IMC a augmenté de manière significative chez les patients sous corticothérapie (P=0,0039). La corticothérapie s’associait également à une diminution importante du percentile
de taille (P=0,0078). Par contre, les mesures anthropométriques ne traversaient pas les percentiles chez les enfants traités au propranolol. Leur
tension artérielle systolique était beaucoup plus faible (P=0,03), mais
aucune valeur hypotensive n’a été enregistrée. Par ailleurs, la durée
médiane du traitement était considérablement plus longue chez les
patients qui prenaient du propranolol (372 jours au lieu de 133;
P=0,0033).
CONCLUSION : Pour soigner les anomalies vasculaires des enfants, le
propranolol n’a pas les mêmes effets défavorables sur l’anthropométrie
que les corticoïdes. Cependant, le traitement est plus long.

accurate and protocolized gathering of information from patients, and
allows for more treatment options and coordination of surgical and
nonsurgical approaches (3). In our centre, a nurse, a professional photographer, two pediatricians and a plastic surgeon comprise such a
multidisciplinary vascular malformation clinic. The traditional oneon-one approach is maintained when the patient is assessed. The team
proposes the therapeutic options, if necessary. The clinic was established when propranolol was introduced as a novel therapeutic option
and we were interested in the effect of the new therapy in a multidisciplinary setting.

METHODS

The Ethics Review Board at Western University (London, Ontario)
approved the study. All patients attending the Vascular Abnormality
Clinic at the Children’s Hospital, London Health Sciences Centre
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Table 1
anatomical distribution of infantile hemangiomas in
patients seen at the Children’s Hospital, london Health
Sciences Centre (london, Ontario) from October 2007 to
February 2012

Table 2
Hemangioma treatment initiated in patients seen at the
Children’s Hospital, london Health Sciences Centre
(london, Ontario) from October 2007 to February 2012

anatomical location
Face
Other head
Pharynx
Torso
Extremity
Total

No therapy initiated

86 (72.3)

60 (50.4)

Medical therapy

18 (15.1)

16 (13.4)

Propranolol

1 (0.9)
22 (18.5)
20 (16.8)
119 (100.0)

Data presented as n (%)

were included. In addition to clinical data and descriptive epidemiological data, anthropometric measurements taken as a part of routine
clinical practice for patients attending the various clinics such as
weight, height (measured by stadiometer [Perspection Enterprises,
USA]; otherwise, Seca 242 mechanical personal measuring rod [Seca,
USA] recumbent for children <2 years of age) and chronological age
were recorded. All personnel performing height and weight measurements were trained for the study. Measurements were performed in
duplicate and repeated if discrepant measurements occurred. The
mean value was recorded. The most recent NHANES III database
(1999 to 2002) was used for all patients (NCHS – 2000 Centers for
Disease Control and Prevention Growth Charts: USA (<www.cdc.
gov/growthcharts/> accessed July 29, 2006).
Body mass index (BMI) was calculated using weight (kg) divided
by the square of height (m2). For the analysis presented, BMI values
were not converted into age-independent z-scores due to the lack of
reference intervals for infants.
Casual blood pressure (BP) was measured from the right arm, resting and seated using an automated oscillometric device (Dinamap,
USA), with the cuff covering two-thirds of the upper arm and the
bladder encircling >80% and <100% of the upper arm circumference.
Because only two readings were performed in some patients, the
second reading was used for analysis. Casual BP percentile was calculated based on the 95th percentile for age, sex and height from the
Fourth Report (1). For children between 17 and 18 years of age, the
normative values for 17-year-old children were used.
The computer program STAT Growth Charts for iPhone (Apple,
USA) (Austin Physician Productivity, USA) was used for these
calculations.
In addition to anthropometry, hemangioma size was recorded at each
visit. All parents were counselled on the signs and symptoms of known
side effects of propranolol and prednisone (hypoglycemia, hyperglycemia, limb cyanosis). They were asked to report these at each visit.
Statistical analysis
Data were collected into a spreadsheet (Excel, Microsoft Corporation,
USA) for Mac version 14.3.1 (Apple, USA) and analyzed using
GraphPad Prism for Mac version 5.0 (GraphPad, USA). Continuous
numerical variables were analyzed for normal distribution using the
D’Agostino & Pearson omnibus test. Normally distributed data were
expressed as mean ± SD and data were compared using the Student’s t
test. Data not normally distributed were expressed as median and
interquartile range using the format 50th percentile (25th percentile,
75th percentile) and, occasionally, the range was also stated. Change
in height percentile per month was calculated for each group (controls, propranolol and corticosteroids) because treatment duration
varied. The mean monthly change in height percentile was compared
with a theoretical median of zero using the Wilcoxon signed-rank test.
This process was then repeated for the calculation and analysis of
change in BMI and systolic BP percentile per month.
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Treatment

7

Steroids

11

Surgical therapy

15 (12.6)

Laser therapy

6

Surgical excision

9

Total

119 (100.0)

Data presented as n (%)

RESULTS

A total of 123 patients (88 female [71.5%]) were seen in the
hemangioma clinic between October 2007 and February 2012. The
median age was 0.8 years (0.3 years, 2.35 years) with a range from
newborn to 15.9 years of age. One hundred nineteen patients had an
IH (87 female [73.1%]), one patient had a cavernous venous malformation and one had a portwine stain. There were two patients with
other lesions such as lymphatic malformations. These patients had a
total of 290 clinic visits, with one to seven appointments per child.
Eighty-seven patients had one lesion, 16 had two and 20 had >2. Table 1
summarizes the anatomical location of IHs in the patient population.
The treatment approach (conservative, surgical treatment and medical) is summarized in Table 2.
Of these, 64 patients were seen repeatedly (between two and seven
times). Thirty-one were observed and received no treatment, six
(18%) underwent laser therapy, nine (27%) received surgical resection
and 18 (55%) underwent medical therapy. Indications for medical
therapy included obstruction of the visual field (n=9), hemifacial
involvement (n=6) and recurrent ulceration/bleeding (n=3). Of the
18 patients who underwent medical therapy, 11 received steroids and
seven underwent propranolol treatment. Of the 11 patients who
received steroids, two could not be analyzed because anthropometric
measurements were not recorded. To assess the side effects of steroids
and propranolol, the remainder of the analysis focused on the patients
who received medical therapy with repeated anthropometry.
The follow-up for these 64 patients was variable. In the control
group, the median follow-up was 364 days (119 days, 553 days); in the
steroid group the median follow-up was 511 days (167 days, 835 days);
and, in the propranolol group, the median follow-up was 372 days
(243 days, 659 days). While the steroid group had a longer follow-up,
this did not reach statistical significance (P=0.529 [Mann-Whitney]).
Prednisone was the corticosteroid used. The median dose was
5.0 mg/kg/day (3.5 mg/kg/day, 5.0 mg/kg/day). The median propranolol
dose was 2.0 mg/kg/day (1.0 mg/kg/day, 2.0 mg/kg/day).
Treatment response to both corticosteroids and propranolol was excellent. The vascular abnormality decreased in size in 11 of 11 patients in the
corticosteroid group and in six of seven patients in the propranolol
group. A minimum 25% reduction in size was noted in all patients
with visual field obstruction or ulceration/bleeding as a treatment
indication. Interestingly, several patients on propranolol who were
weaned off the medication after three months showed subsequent
growth of the lesion. This resulted in restarting the drug and, in some
cases, an increase in dose.
Median treatment duration in the steroid group was 133 days (45 days,
211 days), which was significantly shorter than that of the propranolol group with a median of 372 days (243 days, 659 days; P=0.0033
[Mann-Whitney]).
The change in height percentile per month was analyzed. In the
control group, the median change in height percentile per month was
0.0 (−0.9, +0.4). In contrast, the steroid group had a negative height
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Figure 1) Change in height percentile per month in relation to hemangioma
treatment initiated
velocity, with a median change in height percentile per month of −8.8
(−17.6, −2.7). This was significantly different from zero (P=0.0078
[Wilcoxon signed-rank test]). In the propranolol group, the median
change in height percentile per month was +0.06 (−0.4, +0.8), which
was not significantly different from zero (Wilcoxon signed-rank test).
A comparison of the change in monthly height percentile for each
treatment group is illustrated in Figure 1.
The change in BMI percentile per month was subsequently analyzed. In the control group, the median change in BMI percentile
per month was 0.007 (−0.049, +0.151), which was not significantly
different from zero. In contrast, the steroid group had a negative
height velocity, with a median change in BMI percentile per month
of −0.850 (0.308, 1.975); this was significantly different from zero
(P=0.0039 [Wilcoxon signed-rank test]). In the propranolol group,
the median BMI percentile per month changed by +0.004 (−0.073,
+0.083), which was not significantly different from zero (Wilcoxon
signed-rank test). A comparison of the change in monthly BMI percentile for each treatment group is shown in Figure 2.
Changes in systolic BP percentile per month were analyzed. In the
control group, the median change in systolic BP percentile per month
was 0.4 (−0.1, +1.5) mmHg, which was not significantly different
from zero. In the steroid group, the median increase in systolic BP
percentile per month was +1.7 (−2.9, +7.9), although this did not
reach statistical significance (Wilcoxon signed-rank test). In the
propranolol group, the median systolic BP percentile changed by
−1.1 (−4.7, −1.0), which was significantly different from zero
(P=0.03 [Wilcoxon signed-rank test]). A comparison of the monthly
change in systolic BP percentile is shown in Figure 3. There was no
hypotension observed in the propranolol group.
No cases of hypoglycemia, hyperglycemia or limb cyanosis were
reported. Five patients had their blood glucose level tested, while in
others, no venous blood sampling was pursued because they were
asymptomatic.

DISCUSSION

The present study was a retrospective analysis of prospectively collected data from a new multidisciplinary vascular abnormality clinic in
a single tertiary care centre. A large proportion of patients attended
the clinic only once to obtain a second opinion. The majority of
patients did not receive medical or surgical treatment. This was
expected given the characteristic nature of hemangiomas (2). The
proportion of patients that received medical treatment versus surgical
treatment was slightly biased toward medical treatment. A similar
proportion of patients received corticosteroids and propranolol,
although there was a change over time as more data for propranolol
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Figure 2) Change in body mass index (BMI) percentile per month in relation to hemangioma treatment initiated

Figure 3) Change in systolic blood pressure (SBP) percentile per month in
relation to hemangioma treatment initiated
became available. Not unexpectedly, corticosteroid therapy had a significant negative effect on height and increase in BMI. There was also
an increase in BP, although this did not reach statistical significance.
In contrast, propranolol therapy did not affect height or BMI, but
resulted in a modest, yet statistically significant decrease in BP. No
hypotensive values were recorded. The duration of therapy with propranolol was significantly longer.
For years, corticosteroids have been used as an effective medical
treatment for hemangioma (4,5). The mechanism of action in IH
remains unclear, but increased mast cell number, decreased transcription of cytokines and enhanced transcription of the mitochondrial
cytochrome b gene have been noted following steroid treatment (6).
Our study observed a decrease in height percentile in children
treated with steroids. The negative effect of oral steroids on pediatric height velocity is well documented (7,8). This is assumed to be
due to the greater susceptibility of an actively growing skeleton to
the osteoblast-inhibiting effects of corticosteroids. For example, a sixpatient case series of bone biopsies from children receiving steroids for
nephrotic syndrome found an inverse correlation between rate of bone
formation and dose of prednisone at the time of biopsy (9). There is
less evidence of decreased height velocity in the IH patient population. A previous study, however, supported a correlation between
diminished gain of height with duration of steroid therapy and age at
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initiation of IH treatment (10). Another well-known side effect of
pediatric oral steroids is increased BMI (8). Few, if any, studies to date
report increased BMI following steroid treatment for hemangioma. We
believe our study’s careful collection and analysis of longitudinal
anthropometric data allowed for detection of this negative side effect
in our patients. We also detected an increase – although not statistically significant – in systolic BP in steroid-treated children. In a small
study involving 37 patients with rapidly growing complicated
hemangiomas (11), hypertension was reported in seven, and six were
found to have borderline BP values. The limited number of patients in
our corticosteroid-treatment group may have contributed to the lack
of statistical significance observed in our study.
Since 2008, the beta-blocker propranolol has been shown to be
effective in the treatment of IH (2). It is believed to both constrict
existing blood vessels and inhibit new vascular growth in hemangiomas (12). It acts on beta-adrenergic receptors, decreasing the
release of vascular endothelial growth factor and fibroblast growth
factor (13).
Propranolol is a known antihypertensive with the following side
effects reported in the IH patient population: cool extremities, irritability, lower gastrointestinal upset, emesis, hypotension, poor feeding,
lethargy, bronchospasm and rash (14). To our knowledge, no previous
studies have directly investigated the influence of propranolol on
height and BMI in IH patients. Nevertheless, propranolol has been
used since 2008 without report of adverse height or BMI change,
which is consistent with our findings. We observed a mean propranolol treatment duration of 372 days, which is consistent with the current literature (15,16).
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